Payment overview · 2025
General Payments
$2,404.42
102 reported records · 21 companies
Healthcare provider profile · identity verified
Bruno Bucci, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SANTA ANA, CA · NPI 1407811250
Verified facts
What the public records show
CMS Open Payments records show Bruno Bucci, M.D. received $2,404.42 in general payments during 2025 across 102 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Prolia, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $469.33 | 19.5% | 20 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $278.56 | 11.6% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $273.15 | 11.4% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $227.10 | 9.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.28 | 6.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $157.82 | 6.6% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $123.60 | 5.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.24 | 5.1% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $86.77 | 3.6% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $86.41 | 3.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $84.73 | 3.5% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.68 | 2.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.37 | 2.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.05 | 2.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.46 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.69 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.51 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.55 | 0.9% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $21.05 | 0.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.07 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,404.42 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $278.56 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $275.98 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $193.35 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $166.87 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $157.82 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $149.70 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.20 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.01 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.10 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $99.65 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $86.77 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $86.41 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $82.77 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $79.17 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $60.68 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $59.73 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $49.05 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $49.05 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.47 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.55 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 72 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
72 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 499 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 426 | 126 |
| Losartan Potassium | Losartan Potassium | 343 | 101 |
| Metformin Hcl | Metformin Hcl | 280 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 277 | 79 |
| Omeprazole | Omeprazole | 250 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 61 |
| Valsartan | Valsartan | 181 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 47 |
| Metformin Hcl Er | Metformin Hcl | 171 | 48 |
| Memantine Hcl | Memantine Hcl | 166 | 40 |
| Benazepril Hcl | Benazepril Hcl | 148 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 64 |
| Carvedilol | Carvedilol | 142 | 38 |
| Famotidine | Famotidine | 132 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 45 |
| Allopurinol | Allopurinol | 126 | 36 |
| Ezetimibe | Ezetimibe | 122 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 33 |
| Tradjenta | Linagliptin | 105 | 28 |
| Farxiga | Dapagliflozin Propanediol | 101 | 27 |
| Trulicity | Dulaglutide | 98 | 20 |
| Lisinopril | Lisinopril | 90 | 29 |
| Alendronate Sodium | Alendronate Sodium | 87 | 19 |
| Eliquis | Apixaban | 86 | 25 |
| Glipizide | Glipizide | 84 | 23 |
| Furosemide | Furosemide | 82 | 22 |
| Azithromycin | Azithromycin | 81 | 62 |
| Gabapentin | Gabapentin | 80 | 35 |
| Xarelto | Rivaroxaban | 77 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 22 |
| Prolia | Denosumab | 72 | 46 |
| Vascepa | Icosapent Ethyl | 70 | 13 |
| Sertraline Hcl | Sertraline Hcl | 69 | 20 |
| Potassium Chloride | Potassium Chloride | 68 | 24 |
| Alprazolam | Alprazolam | 63 | 17 |
| Ozempic | Semaglutide | 63 | 14 |
| Lovastatin | Lovastatin | 62 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 20 |
| Donepezil Hcl | Donepezil Hcl | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 11 |
| Hydrocortisone | Hydrocortisone | 53 | 33 |
| Memantine Hcl Er | Memantine Hcl | 52 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 49 | 15 |
| Finasteride | Finasteride | 46 | 14 |
| Montelukast Sodium | Montelukast Sodium | 46 | 15 |
| Trazodone Hcl | Trazodone Hcl | 45 | 12 |
| Nystatin | Nystatin | 42 | 23 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 39 | 15 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 19 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 15 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vivelle-Dot | Estradiol | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,404.42 · 102 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, AREXVY, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQEMBI, MOUNJARO, OTEZLA, Omnipod, Ozempic, PROLIA, QULIPTA, RELISTOR, REPATHA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error